Development of an ELISA for measurement of BCARI protein in human breast cancer tissue

Clinical Chemistry

Volumn 50, Issue 8, 2004, Pages 1356-1363

  Grebenchtchikov, Nicolai ^a   Brinkman, Arend ^b   Van Broekhoven, Simone P J ^b   De Jong, Danielle ^b   Geurts Moespot, Anneke ^a   Span, Paul N ^a   Peters, Harry A ^b   Portengen, Henk ^b   Foekens, John A ^b   Sweep, C G J ^a   Dorssers, Lambert C J ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BREAST CANCER ANTIESTROGEN RESISTANCE 1; PROTEIN DERIVATIVE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL CELL; BREAST CANCER; CANCER TISSUE; CHICKEN; CONTROLLED STUDY; CROSS REACTION; CYTOSOL; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN FAMILY; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; RABBIT; VALIDATION PROCESS; WESTERN BLOTTING;

ANIMALS; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CHICKENS; CRK-ASSOCIATED SUBSTRATE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEINS; RABBITS; RETINOBLASTOMA-LIKE PROTEIN P130; SENSITIVITY AND SPECIFICITY;

BACTERIA (MICROORGANISMS); GALLUS GALLUS; MURINAE; ORYCTOLAGUS CUNICULUS;

EID: 3242755885     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.029868     Document Type: Article

References (18)

1. Brinkman A, Van der Flier S, Kok EM, Dorssers LCJ. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 2000;92:112-20.
2. Van der Flier S, Van der Kwast TH, Claassen CJC, Timmermans M, Brinkman A, Henzen-Logmans SC, et al. Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue. Int J Biol Markers 2001;16:172-8.
3. Van der Flier S, Brinkman A, Look MP, Kok EM, Meijer-Van Gelder ME, Klijn JGM, et al. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 2000;92:120-7.
4. O'Neill GM, Fashena SJ, Golemis EA. Integrin signalling: a new Cas(t) of characters enters the stage. Trends Cell Biol 2000;10:111-9.
5. Bouton AH, Riggins RB, Bruce-Staskal PJ. Functions of the adapter protein Cas: signal convergence and the determination of cellular responses. Oncogene 2001;20:6448-58.
6. Law SF, Estojak J, Wang BL, Mysliwiec T, Kruh G, Golemis EA. Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol 1996;16:3327-37.
7. Law SF, Zhang YZ, Klein-Szanto AJP, Golemis EA. Cell cycle-regulated processing of HEF1 to multiple protein forms differentially targeted to multiple subcellular compartments. Mol Cell Biol 1998;18:3540-51.
8. Grebenschikov N, Geurts-Moespot A, De Witte H, Heuvel J, Leake R, Sweep F, et al. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type 1 (PAI-1) in breast tumor cytosols. Int J Biol Markers 1997;12:6-14.
9. Grebenschikov N, Sweep F, Geurts A, Andreasen P, De Witte H, Schousboe S, et al. ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1). Int J Cancer 1999;81:598-606.
10. Grebenchtchikov N, Sweep CGJ, Geurts-Moespot A, Piffanelli A, Foekens JA, Benraad TJ. An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood. J Immunol Methods 2002;268:219-31.
11. Van der Flier S, Chan CMW, Brinkman A, Smid M, Johnston SRD, Dorssers LCJ, et al. BCAR1/p130Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas. Int J Cancer 2000;89:465-8.
12. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E. O. R. T. C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer 1980;16:1513-5.
13. Foekens JA, Portengen H, Van Putten WU, Peters HA, Krijnen HUM, Alexieva-Figusch J, et al. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 1989;49:5823-8.
14. Honda H, Oda H, Nakamoto T, Honda Z, Sakai R, Suzuki T, et al. Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat Genet 1998;19:361-5.
15. Black DS, Bliska JB. Identification of p130Cas as a substrate of Yersinia YopH (Yop51), a bacterial protein tyrosine phosphatase that translocates into mammalian cells and targets focal adhesions. EMBO J 1997;16:2730-44.
16. Persson C, Carballeira N, Wolf-Watz H, Fällman M. The PTPase YopH inhibits uptake of Yersinia, tyrosine phosphorylation of p130Cas and FAK, and the associated accumulation of these proteins in peripheral focal adhesions. EMBO J 1997;16:2307-18.
17. Li E, Stupack DG, Brown SL, Klemke R, Schlaepfer DD, Nemerow GR. Association of p130CAS with phosphatidylinositol-3-OH kinase mediates adenovirus cell entry. J Biol Chem 2000;275:14729-35.
18. Zhang XA, He B, Zhou B, Liu L. Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration. J Biol Chem 2003;278:27319-28.